Background The widespread use of Immune checkpoint-inhibitors (ICI) has revolutionised
treatment of multiple cancer types. However, selecting patients who may benefit from ICI …

While the field of precision oncology is rapidly expanding and more targeted options are
revolutionizing cancer treatment paradigms, therapeutic resistance particularly to …

Cancer cells favor the generation of myeloid cells with immunosuppressive and
inflammatory features, including myeloid-derived suppressor cells (MDSCs), which support …

Although more than a decade has passed since the approval of immune checkpoint
inhibitors (ICIs) for the treatment of melanoma and non-small-cell lung, breast and …

Immune checkpoints inhibitors (ICIs) have markedly improved the therapeutic management
of advanced NSCLC and, more recently, they have demonstrated efficacy also in the early …

Non-small cell lung cancer (NSCLC) constitutes the majority of the lung cancer population
and the prognosis is poor. In recent years, immunotherapy has become the standard of care …

The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly
influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical …

Lung cancer is a leading global cause of mortality, with non-small cell lung cancer (NSCLC)
accounting for a significant portion of cases. Immune checkpoint inhibitors (ICIs) have …

Introduction Immune checkpoint inhibitors have made a paradigm shift in the treatment of
non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust …

Immunotherapy has improved survival rates in patients with cancer, but identifying those
who will respond to treatment remains a challenge. Advances in proteomic technologies …